Immuron Ltd ADR (IMRN) Stock Price, Quote & News

Company Profile

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune su...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9824 5254

Fax: 61 3 9822 7735

Website: www.immuron.com.au

Address:

62 Lygon Street, Level 3 Carlton South, Carlton, Australia

Li9999 Jul. 30 at 12:20 AM

$IMRN AH very good sign for tomorrow

0 · Reply

Baseball89 Jul. 29 at 2:16 PM

$CLSD $ABP is climbing. $IMRN solid

0 · Reply

Baseball89 Jul. 29 at 9:53 AM

$IMRN when is this going to be pumped again?

1 · Reply

Timtheshark Jul. 28 at 2:35 PM

$IMRN – Estimated Catalysts (Next ~18 Months) 🚀 1. Sep 2025 – IND submission (IMM‑529): Regulatory greenlight → +10–20% 2. Oct–Nov 2025 – Q3 FY26 sales: Beat & raise → +10–20% 3. Oct 2025 – CHIM + field topline: ≥20–30% → +30–40% 4. Q1 2026 – FDA EOP2 meeting (Travelan): Path confirmed → +20–30% 5. Q1 2026 – IMM‑529 Phase II start: Dosing begins → +10–20% 6. Q1–Q2 2026 – IMM‑986 preclinical topline (VRE): Positive in vivo data → +10–20% 7. Q1 2026 – ProIBS launch (AU/NZ): First royalties → +5–10% 8. Q2 2026 – CVS/Walgreens/Boots launch: Retail scale-up → +20–30% 9. Q2–Q3 2026 – CPG deal (Nestlé/GSK etc): Branding & global rollout → +30–40% 10. H1 2026 – Travelan Phase III protocol finalized → +5–10% 11. H2 2026 – Analyst coverage + IR roadshow → +20–30% 12. H2 2026 – IND submission for Phase III → +5–10% 🧬 Pipeline = mapped. 📈 Sales, partnerships, distribution, analyst coverage = upside anytime.

0 · Reply

Baseball89 Jul. 25 at 5:43 PM

$ABP $IMRN a sleeper right now

0 · Reply

twisrs Jul. 24 at 7:54 PM

$PYXS $IMRN

1 · Reply

Baseball89 Jul. 24 at 3:29 PM

$HCTI $ABP ---volume picking up $IMRN ----solid ++

1 · Reply

Timtheshark Jul. 24 at 12:21 PM

$IMRN @ALDX_Bull Appreciate the take! I actually agree that October (CHIM + Field Data) is where big institutional entries likely come in. But I do think August has its role: it sets up the move. 💡 If IMM-529 IND and IMM-986 preclinical data land cleanly, we’ll likely see: • Shelf-free window = price freedom • Float tightening (only 6.7M O/S!) • MM facilitation shifts from capping to ramping • Fast repricing ahead of deeper catalysts So in short: August = ignition 🧨 October = acceleration 🚀 Let’s see how HC plays it — but I’m positioned for both.

0 · Reply

Baseball89 Jul. 23 at 8:15 PM

$IMRN this can very easily run $25 to $35 price target. Solid performing biopharmaceutical.

0 · Reply

Timtheshark Jul. 23 at 5:14 PM

$IMRN – The Most Asymmetric Biotech Play in 2025? Here is, In my view, a realistic, milestone-based value ladder for Immuron (6.7M shares O/S), assuming no Phase III is needed for FDA approval of Travelan: 📆 Trigger-Based Price Targets & Est. Market Cap Event Est. Price Est. BV ✅ Today (Jul ’25) $1.70 $11M - IMM‑986 Preclin (Aug) $3.20 $21M - IMM‑529 IND (Aug) $3.80 $25M - CHIM + Field Data (Oct) $5.00 $33M - IMM‑529 Phase II Start (Q4) $6.00 $40M - FDA EOP2 Mtg (Q4) $6.50 $44M - ProIBS Launch (Q1 ’26) $7.50 $50M - BLA Submission (H1 ’26) $9.00 $60M - Travelan FDA Approval (H2 ’26) $13.00 $87M - IMM‑986 PRV/QIDP (2026–27) $17.00 $114M - Strategic Deal / Takeout $20.00 $134M 🚀 Every step unlocks major asymmetric upside. Even a base case path should yield 5–10x from here. Do your DD. Not advice. But this must be the most slept-on microcap in biotech right now.

1 · Reply

Immuron - FY25 global sales exceed projection, up 49% on prior year

May 30, 2025, 6:00 AM EDT - 2 months ago

Immuron Letter to Shareholders: Projects Update

Apr 10, 2025, 6:00 PM EDT - 3 months ago

Immuron Travelan® highest sales in history

Mar 5, 2025, 6:00 AM EST - 5 months ago

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Jan 17, 2025, 6:00 AM EST - 6 months ago

Immuron Travelan® continued strong sales growth

Jan 15, 2025, 6:00 AM EST - 7 months ago

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Jan 14, 2025, 6:00 AM EST - 7 months ago

Immuron Announces Travelan® Clinical Trial Update

Dec 2, 2024, 6:00 AM EST - 8 months ago

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Nov 21, 2024, 6:33 PM EST - 8 months ago

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Nov 18, 2024, 8:30 AM EST - 9 months ago

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Oct 16, 2024, 6:00 AM EDT - 10 months ago

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

Oct 4, 2024, 6:30 AM EDT - 10 months ago

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Sep 19, 2024, 9:42 AM EDT - 11 months ago

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Sep 5, 2024, 11:54 AM EDT - 11 months ago

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOSS GOVX

Aug 16, 2024, 6:00 AM EDT - 1 year ago

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Aug 15, 2024, 6:14 PM EDT - 1 year ago

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Aug 7, 2024, 6:00 AM EDT - 1 year ago

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Jul 2, 2024, 6:00 AM EDT - 1 year ago

Immuron requests pre-IND meeting for IMM-529 with FDA filing

May 31, 2024, 6:00 AM EDT - 1 year ago

Immuron Board Changes

May 31, 2024, 6:00 AM EDT - 1 year ago

Immuron CEO Steven Lydeamore to present at Peak Sky High

May 7, 2024, 6:00 AM EDT - 1 year ago

Immuron Limited to Present at the Emerging Growth Conference

May 3, 2024, 6:00 AM EDT - 1 year ago

Immuron Director Resignation

Apr 15, 2024, 6:00 AM EDT - 1 year ago

Immuron to host Live Virtual Event

Apr 10, 2024, 6:00 AM EDT - 1 year ago

Immuron Travelan® sales continued strong growth

Mar 7, 2024, 6:00 AM EST - 1 year ago

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Feb 21, 2024, 6:00 AM EST - 1 year ago

Immuron Presentation Australian Biologics Festival 2024

Feb 13, 2024, 6:00 AM EST - 1 year ago

Immuron achieves record Travelan® sales

Feb 8, 2024, 6:00 AM EST - 1 year ago

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Jan 16, 2024, 6:00 AM EST - 1 year ago

Immuron achieves record half yearly Travelan® sales

Dec 22, 2023, 6:00 AM EST - 1 year ago

Immuron Clinical Trials Update

Dec 4, 2023, 6:00 AM EST - 1 year ago

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Nov 13, 2023, 6:00 PM EST - 1 year ago

Immuron CEO Steven Lydeamore Investor Webinar Presentation

Oct 30, 2023, 7:21 AM EDT - 1 year ago

Immuron CEO Steven Lydeamore presented at AusBioInvest

Oct 18, 2023, 6:00 AM EDT - 1 year ago

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Oct 11, 2023, 6:00 AM EDT - 1 year ago

Immuron achieves record quarterly Travelan® sales

Sep 18, 2023, 7:30 AM EDT - 2 years ago

Immuron Limited Announces Participation in the LD Micro Main Event XVI

Sep 13, 2023, 6:00 AM EDT - 2 years ago

Immuron achieves record monthly Travelan® sales

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

Aug 14, 2023, 6:00 AM EDT - 2 years ago

Immuron to present at the Military Health System Research Symposium

Jul 25, 2023, 6:00 AM EDT - 2 years ago

Immuron Announces First Patients Enrolled in Travelan® Clinical Study

Jul 24, 2023, 6:00 AM EDT - 2 years ago

Immuron CEO, Steven Lydeamore to present at Bioshares

Jul 11, 2023, 6:00 AM EDT - 2 years ago

Immuron Business Update - Ateria Health launches Juvia™ in Australia

Jul 5, 2023, 6:00 AM EDT - 2 years ago

Immuron FY23 Sales increase 136% on FY22 Sales

Jun 30, 2023, 6:00 AM EDT - 2 years ago

Immuron Chairman Transition

Jun 22, 2023, 6:00 AM EDT - 2 years ago

Immuron Business Update: Letter to Shareholders

May 30, 2023, 6:00 AM EDT - 2 years ago

Immuron Initiates Recruitment of Travelan® Clinical Study

May 16, 2023, 7:30 AM EDT - 2 years ago

Immuron Limited Announces Participation in the LD Micro Invitational XIII

May 8, 2023, 6:35 AM EDT - 2 years ago

Immuron stock rockets after FDA removes hold on IND of infectious diarrhea treatment

May 8, 2023, 6:00 AM EDT - 2 years ago

Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation

Li9999 Jul. 30 at 12:20 AM

$IMRN AH very good sign for tomorrow

0 · Reply

Baseball89 Jul. 29 at 2:16 PM

$CLSD $ABP is climbing. $IMRN solid

0 · Reply

Baseball89 Jul. 29 at 9:53 AM

$IMRN when is this going to be pumped again?

1 · Reply

Timtheshark Jul. 28 at 2:35 PM

0 · Reply

Baseball89 Jul. 25 at 5:43 PM

$ABP $IMRN a sleeper right now

0 · Reply

twisrs Jul. 24 at 7:54 PM

$PYXS $IMRN

1 · Reply

Baseball89 Jul. 24 at 3:29 PM

$HCTI $ABP ---volume picking up $IMRN ----solid ++

1 · Reply

Timtheshark Jul. 24 at 12:21 PM

0 · Reply

Baseball89 Jul. 23 at 8:15 PM

$IMRN this can very easily run $25 to $35 price target. Solid performing biopharmaceutical.

0 · Reply

Timtheshark Jul. 23 at 5:14 PM

1 · Reply

Baseball89 Jul. 23 at 3:11 PM

$IMRN this stock traded over $14 back in 2020. It should always be actively trading. Solid company with solid results and profitable. Stock should be going up in value.

0 · Reply

Li9999 Jul. 22 at 4:04 PM

$IMRN up 🔝 ⬆️ 🆙 up

0 · Reply

bjhbj Jul. 22 at 1:51 AM

$IMRN A big catalyst is coming up.

1 · Reply

RG_trades Jul. 21 at 6:07 PM

$IMRN very bullish suprised still so low. hold

0 · Reply

Baseball89 Jul. 21 at 2:41 PM

$IMRN this has got to be better than crypto. When run? Was over $15 in 2020. Why so low?

1 · Reply

Li9999 Jul. 21 at 12:05 PM

$IMRN extremely bullish show it today

1 · Reply

Timtheshark Jul. 21 at 12:14 AM

$IMRN confirmed: ATM overhang removed The full 800k ADS ATM was used on July 17 (record sales PR). 📄 Appendix 708A just filed (July 21) = 32.9M new shares issued on ASX = exactly 823k ADS. ✅ No new ATM round has been activated. ⚠️ If they want to use the remaining $13M, they must file a new 3B + SEC update + broker deal. ⏳ That means we’ll see it coming – no hidden dilution ahead. 🚀 With the ATM overhang removed, breakout now possible. https://hotcopper.com.au/threads/ann-notice-under-section-708a.8673518/

1 · Reply

Timtheshark Jul. 19 at 5:31 AM

$IMRN already had ~$5M in cash — enough to last until Travelan revenue covers the burn rate — so raising another ~$2M via ATM right before the IND filing in August is actually bullish. 💡 FDA requires sufficient funding before accepting INDs. This likely confirms: ✅ IND package is finalized ✅ Cash runway secured ✅ No risk of rejection on financial grounds They basically cleaned up the balance sheet before the catalyst storm hits. 🚀 Now float is still tiny (~4.6M ADS), ATM done, and upcoming FDA/DoD events flips the setup. Classic ‘load-the-dip’ moment before the real storm hits. 🔥

0 · Reply

Li9999 Jul. 18 at 10:01 PM

$IMRN can someone tell me why?🥲

1 · Reply

MarioRigby Jul. 18 at 7:28 PM

$IMRN looks somewhat interesting..

0 · Reply

Timtheshark Jul. 18 at 6:50 PM

$IMRN – absurdly undervalued: • Market cap ~$11M • Cash ~$6.9M → EV just ~$4M • 2+ years cash runway • No debt, low burn (~$2.8M/year) • Travelan sales $5.3M (+46% YoY) • EV/S < 0.8 (!) • Travelan alone may now cover burn → near break-even • ProIBS launch Q1 2026 = additional $2–3M revenue • Clinically validated antibody platform • 3 pipeline assets (C. diff, VRE, ETEC) • First major catalyst in Aug 2025 • Float now ~4.6M ADS — still extremely low How can this be? 🤯😂

1 · Reply

Baazigar30 Jul. 18 at 5:34 PM

$PLRZ imo this stock should run huge like last time 🚀🚀🚀🚀 This is important part of PR Following the Private Placement, we have a cash balance of approximately $15.68 million. With the full exercise of the warrants issued in that transaction, we have meaningfully simplified our capital structure, eliminating a significant source of potential dilution and overhang. We believe this positions us well to enhance long-term shareholder value and better reflect the strength of our underlying business. $IMRN This is my number #1 selection Imo do ur own dd. Few points 👇 Float :3.82M Immuron Travelan® highest sales in history CATALYSTS: •Launch plans underway for ProIBS® in Australia •Immuron anticipates IMM-529 (Clostridiodes difficile infection) IND submission to the FDA in August 2025 •Immuron anticipates IMM-986 (Vancomycin-resistant enterococci) pre-clinical research results in August 2025 Both holding for big money

1 · Reply

Market Cap	9.82M
Revenue (ttm)	3.22M
Net Income (ttm)	-4.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-141.30%
Debt to Equity Ratio	0.00

Volume	76,600
Avg Vol	290,810
Day's Range	N/A - N/A
Shares Out	5.88M
Stochastic %K	18%
Beta	0.82
Analysts	Strong Sell
Price Target	$5.00